Leo Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEO PHARM
LEO PHARM has thirteen approved drugs.
There are thirteen US patents protecting LEO PHARM drugs.
There are two hundred and thirteen patent family members on LEO PHARM drugs in thirty-eight countries and twenty-two supplementary protection certificates in fourteen countries.
Summary for Leo Pharm
| International Patents: | 213 |
| US Patents: | 13 |
| Tradenames: | 9 |
| Ingredients: | 8 |
| NDAs: | 13 |
| Drug Master File Entries: | 2 |
| Patent Litigation for Leo Pharm: | See patent lawsuits for Leo Pharm |
Drugs and US Patents for Leo Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Pharma As | FINACEA | azelaic acid | AEROSOL, FOAM;TOPICAL | 207071-001 | Jul 29, 2015 | RX | Yes | Yes | 10,117,812 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Leo Pharma As | FINACEA | azelaic acid | AEROSOL, FOAM;TOPICAL | 207071-001 | Jul 29, 2015 | RX | Yes | Yes | 7,700,076 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Leo Pharma As | ENSTILAR | betamethasone dipropionate; calcipotriene | AEROSOL, FOAM;TOPICAL | 207589-001 | Oct 16, 2015 | RX | Yes | Yes | 9,119,781*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Leo Pharma As | ENSTILAR | betamethasone dipropionate; calcipotriene | AEROSOL, FOAM;TOPICAL | 207589-001 | Oct 16, 2015 | RX | Yes | Yes | 9,566,286 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Leo Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leo Pharma As | FINACEA | azelaic acid | AEROSOL, FOAM;TOPICAL | 207071-001 | Jul 29, 2015 | 8,435,498 | ⤷ Start Trial |
| Leo Pharma As | FINACEA | azelaic acid | AEROSOL, FOAM;TOPICAL | 207071-001 | Jul 29, 2015 | 10,322,085 | ⤷ Start Trial |
| Leo Pharma As | DOVONEX | calcipotriene | CREAM;TOPICAL | 020554-001 | Jul 22, 1996 | RE39706 | ⤷ Start Trial |
| Leo Pharma As | TACLONEX | betamethasone dipropionate; calcipotriene | SUSPENSION;TOPICAL | 022185-001 | May 9, 2008 | RE39706 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LEO PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 0.01% | ➤ Subscribe | 2006-05-19 |
| ➤ Subscribe | Topical Foam | 15% | ➤ Subscribe | 2017-09-14 |
| ➤ Subscribe | Ointment | 0.1% | ➤ Subscribe | 2010-09-09 |
| ➤ Subscribe | Ointment | 0.005%/0.064% | ➤ Subscribe | 2010-03-31 |
| ➤ Subscribe | Gel | 15% | ➤ Subscribe | 2012-07-27 |
| ➤ Subscribe | Gel | 0.05% | ➤ Subscribe | 2010-12-01 |
| ➤ Subscribe | Ointment | 0.03% | ➤ Subscribe | 2010-11-22 |
International Patents for Leo Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2579852 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2008152444 | ⤷ Start Trial |
| Australia | 2006273697 | ⤷ Start Trial |
| Russian Federation | 2576607 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Leo Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2460806 | PA2025511 | Lithuania | ⤷ Start Trial | PRODUCT NAME: DELGOCITINIBAS VISOMIS FORMOMIS SAUGOMOMIS PAGRINDINIO PATENTO; REGISTRATION NO/DATE: EU/1/24/1851 20240919 |
| 2460806 | 122025000013 | Germany | ⤷ Start Trial | PRODUCT NAME: DELGOCITINIB IN ALLEN DURCH DAS GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1851 20240919 |
| 2460806 | CA 2025 00010 | Denmark | ⤷ Start Trial | PRODUCT NAME: DELGOCITINIB I ALLE FORMER BESKYTTET AF BASISPATENTET; REG. NO/DATE: EU/1/24/1851 20240923 |
| 2435024 | 21C1020 | France | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
